MedTrace Logo

High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)

NCT06489691 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-01-22

No results posted yet for this study

Summary

To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live \>2500m on 6-minute walk distance (6MWD)

Conditions

  • High Altitude Pulmonary Hypertension

Interventions

OTHER

6-minute walk test (6MWT)

6-minute walk test (6MWT) will be performed according to clinical standards

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Talant M Sooronbaev, Prof. Dr. · National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

  • Silvia Ulrich, Prof. Dr. · University Hospital Zurich, Department of Pulmonology

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-02
Primary Completion
2024-09-27
Completion
2024-09-27

Countries

  • Kyrgyzstan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06489691 on ClinicalTrials.gov